GSK has exciting news! The U.S. Food and Drug Administration (FDA) just approved Exdensur (depemokimab-ulaa) for maintenance treatment of severe asthma in both adults and kids aged 12 and older. This approval is a big deal, especially for those with the eosinophilic phenotype of asthma, which can be tricky to manage.
The FDA based its decision on two key studies: SWIFT-1 and SWIFT-2. These trials showed that patients using Exdensur saw a marked decrease in asthma attacks—58% and 48% in the two studies compared to those taking a placebo. That’s a significant reduction, making asthma management much more manageable.
In another important finding, patients on Exdensur were less likely to need hospital care during asthma flare-ups. Only 1% and 4% required hospitalization compared to 8% and 10% in the placebo groups from the trials. This strong performance suggests a 72% cut in the need for emergency interventions. What’s more, patients tolerated this medication well, experiencing side effects similar to those on a placebo.
GSK’s Kaivan Khavandi noted, “With just two doses a year, doctors can now offer serious protection against asthma flare-ups.” This is a significant step forward for asthma treatments, moving towards less frequent dosing but sustained efficacy.
Severe asthma affects around 2 million Americans, with many facing recurrent symptoms that lead to frequent hospitalizations. Despite the effectiveness of biologics like Exdensur, only a small fraction of eligible patients (about 20%) currently use them. There’s a real opportunity for improvement here, especially since 73% of doctors believe that longer dosing intervals could help more patients consider these treatments.
Dr. Geoffrey Chupp from Yale University highlighted that current methods can be inconvenient, which sometimes leads to inconsistent use. He emphasized that a longer-lasting medication like Exdensur could simplify treatment for many.
Tonya Winders, President of the Global Allergy & Airways Patient Platform, echoed these sentiments, remarking on the relief that innovative treatments offer for people combating severe asthma daily.
Exdensur isn’t just a U.S. phenomenon; it has also received approval in the UK and is under review in other markets, including Europe, China, and Japan.
Severe asthma, marked by the need for high-dose inhaled corticosteroids along with additional treatments, impacts a large number of individuals. Type 2 inflammation drives the disease in more than 80% of these cases, often resulting from elevated eosinophils, a type of white blood cell.
In summary, the approval of Exdensur marks a promising advancement in treating severe asthma. As more patients gain access to effective medications, the healthcare system may see fewer emergency visits and improved overall health outcomes.
For further details, you can view the official prescribing information here.
